Global Xerostomia Therapeutics Market Report 2024

The xerostomia therapeutics market size has grown strongly in recent years. It will grow from $2.04 billion in 2023 to $2.14 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth observed during the historic period can be attributed to several factors, including increasing incidences of xerostomia in the geriatric population, research and development of efficient products for xerostomia, growing awareness about xerostomia-related products, the increasing prevalence of medical conditions, and the rising prevalence of chronic diseases.

The xerostomia therapeutics market size is expected to see strong growth in the next few years. It will grow to $2.65 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%. The anticipated growth in the forecast period can be attributed to several factors, including the easy availability of cost-effective medications in the market, increased prevalence of oral health conditions, rising awareness among healthcare practitioners, government initiatives, and increased medication use. Major trends expected in the forecast period include the emergence of artificial saliva and saliva substitutes, technological advancements and product innovations, the adoption of personalized medicine and targeted therapies, the expansion of telehealth and remote monitoring, and the rise of non-invasive therapies.

The increasing utilization of chemotherapy in cancer care is anticipated to drive the expansion of the xerostomia therapeutics market in the future. Chemotherapy, a cornerstone of cancer treatment, employs potent medications to target and suppress the proliferation of cancer cells, contributing significantly to improved patient outcomes. Xerostomia therapeutics encompass various interventions such as saliva-stimulating medications and mouth rinses designed to alleviate dry mouth symptoms, enhance saliva production, and improve taste sensation, thereby facilitating proper nutrition and oral comfort for patients undergoing cancer treatment. For example, as of January 2022, the National Cancer Institute reported an estimated 18.1 million cancer survivors in the United States, constituting 5.4% of the total population. By 2032, this number is projected to reach 22.5 million worldwide, reflecting a 24.4% increase from current estimates. Hence, the rising adoption of chemotherapy in cancer management is a key driver behind the growth of the xerostomia therapeutics market.

Prominent companies operating in the xerostomia therapeutics sector are actively engaged in the development of saliva substitutes that emulate the natural properties of saliva, offering relief to individuals experiencing xerostomia. These substitutes effectively mitigate dry mouth discomfort by providing moisture, lubrication, pH balance, and cleansing to the oral cavity, ultimately promoting better oral health and enhanced quality of life. For instance, in September 2021, ICPA Health Products, a pharmaceutical firm based in India, introduced Wet Mouth, a saliva substitute formulated with advanced mouth moisturizing technology. Wet Mouth offers relief from dry mouth symptoms for up to four hours, maintaining oral pH balance without alcohol or sugar content, while also serving as a refreshing peppermint-flavored mouthwash and breath freshener.

In June 2022, Eagle Pharmaceuticals Inc., a US-based pharmaceutical company, completed the acquisition of Acacia Pharma Group plc for $104 million. This strategic move positions Eagle Pharmaceuticals as a significant player in the xerostomia therapeutics market, enhancing its product portfolio, market access, research and development capabilities, and potential for synergies and operational efficiencies. Acacia Pharma Group plc, headquartered in the UK, specializes in the development and commercialization of products aimed at addressing xerostomia and related conditions.

Major companies operating in the xerostomia therapeutics market are Bayer AG, 3M Company, GlaxoSmithKline plc, Colgate-Palmolive Company, Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Church & Dwight Co. Inc., Cipla Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Synedgen Inc., Sunstar Suisse S.A., Advanz Pharma Corp., Pharmascience Inc., Mission Pharmacal Company, Dentaid Ltd., Cyclacel Pharmaceuticals Inc., Parnell Pharmaceuticals Holdings Ltd., Teva Pharmaceutical Industries Ltd., Forward Science Holding Inc., ICPA Health Products Ltd., CCMed Ltd., Bio Cosmetics Laboratories S.L., Quest Products LLC, Acacia Pharma, Saliwell Limited, OraCoat, Oralieve UK Ltd., OraPharma Inc., OraVital Inc.

North America was the largest region in the xerostomia therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xerostomia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the xerostomia therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Xerostomia therapeutics encompass treatments and medications utilized to manage dry mouth, a condition characterized by reduced saliva production. These therapies aim to alleviate symptoms such as difficulty swallowing and tasting, as well as prevent dental issues.

The main types of xerostomia therapeutics include artificial saliva or saliva substitutes, and salivary stimulants. Artificial saliva or saliva substitutes are products specifically formulated to replicate the natural properties of saliva, providing lubrication, moisture, and protection to the oral tissues. They are distributed through various channels including hospital pharmacies, retail pharmacies, drug stores, mail order pharmacies, as well as hypermarkets and supermarkets, catering to both adult and pediatric end users.

The xerostomia therapeutics market research report is one of a series of new reports that provides xerostomia therapeutics market statistics, including xerostomia therapeutics industry global market size, regional shares, competitors with a xerostomia therapeutics market share, detailed xerostomia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the xerostomia therapeutics industry. This xerostomia therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The xerostomia therapeutics market consists of revenues earned by entities by providing services such as medical consultations, pharmacological assistance, dental care, patient education, support services, and research and development, all geared towards treating and managing dry mouth. The market value includes the value of related goods sold by the service provider or included within the service offering. The xerostomia therapeutics market also includes sales of oral moisturizers, dental products such as fluoride treatments and saliva-stimulating mouthwashes, and oral lubricants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.